Skip to content

Continuous Monitoring and Management of Vaginal Health Via Multifunctional OCT/OCTA/OCE Endoscopy

Continuous Monitoring and Management of Vaginal Health Via Multifunctional 1.7um Optical Coherence Tomography/Angiography Endoscopy

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04737616
Enrollment
90
Registered
2021-02-04
Start date
2020-07-16
Completion date
2026-07-31
Last updated
2025-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Genitourinary Syndrome of Menopause

Keywords

OCT: Optical coherence tomography, CO2: Carbon dioxide, GSM: genitourinary syndrome of menopause, OCE: Optical coherence angiography, OCTA:Optical coherence tomography with angiography

Brief summary

We have recently developed and optimized a vaginal Optical Coherence tomography/angiography endoscopy imaging system. This technology is able to obtain a comprehensive image of the vaginal epithelium, blood vessels, and lamina propria. The primary focus of this study is establishing the Optical Coherence Tomography system's capability of capturing vaginal changes that occur before and after menopause, as well as before and after treatment with fractional-CO2 laser therapy. There are two aims of this study. Aim 1: 1\. To determine the feasibility and sensitivity of the integrated optical coherence endoscope to assess vaginal tissue integrity in pre, peri and postmenopausal women. Aim 2: To optically visualize the effects of fractional-CO2 laser treatment on vaginal tissue over the course of C02 vaginal laser therapy.

Detailed description

The vaginal Optical Coherence tomography/angiography endoscopy imaging system. This technology is able to obtain a comprehensive image of the vaginal epithelium, blood vessels, and lamina propria. The primary focus of this study is establishing the Optical Coherence Tomography system's capability of capturing vaginal changes that occur before and after menopause, as well as before and after treatment with fractional-CO2 laser therapy. There are two aims of this study. Aim 1: To determine the feasibility and sensitivity of the integrated optical coherence endoscope to assess vaginal tissue integrity in pre, peri and postmenopausal women We will enroll up to 90 women (age: 18 and older) who will be classified as pre-menopausal, peri- menopausal, or post-menopausal. There will be 30 women in each group. All enrolled subjects will first complete informed consents. They will then fill out a questionnaire (the vulvovaginal symptom questionnaire) about their vaginal health. This will be followed by a pelvic exam to determine the vaginal health (vaginal health index) and to obtain a vaginal swab for assessment of the vaginal microbiome . This will be followed by OCT scan of the vaginal tissue. There will be only one visit. Aim 2: To optically visualize the effects of fractional-CO2 laser treatment on vaginal tissue over the course of C02 vaginal laser therapy. Up to thirty Post-menopausal subjects with GSM who desire fractional-CO2 laser therapy, will be recruited. Each visit will include: completion of a questionnaire (the vulvovaginal symptom questionnaire) about their vaginal health; followed by a pelvic exam to determine the vaginal health (vaginal health index) and to obtain a vaginal swab for assessment of the vaginal microbiome and an OCT scan of the vaginal tissue before the CO2 vaginal laser treatment. This group will have a total of three visits with CO2 laser treatments. There will be a fourth visit which will include all the above study procedures except the CO2 laser treatment. Subjects who complete 3 laser treatments will be offered participation in long term follow up with repeat OCT imaging every 3 months at 3, 6, 9 and 12 months after the final laser treatment to study the long- term effects of the laser treatment on the vaginal tissue.

Interventions

DEVICECO2 laser

Fractional CO2 vaginal laser for genitourinary syndrome of menopause

DEVICEOCT

Optical coherence tomography endoscope

Sponsors

National Institutes of Health (NIH)
CollaboratorNIH
University of California, Irvine
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Aim 1: . Women who are premenopausal, peri-menopausal and postmenopausal Aim 2: . Postmenopausal women with genitourinary syndrome of menopause

Exclusion criteria

* history of pelvic irradiation * Current pregnant or breastfeeding * Use of hormone replacement therapy within three months of study enrollment * Inability to read and understand english * inability to follow research instructions

Design outcomes

Primary

MeasureTime frameDescription
Vaginal epithelial thickness (VET)2 yearsVaginal epithelium thickness measured with the OCT.

Secondary

MeasureTime frameDescription
Lactobacillus abundance2 yearsLactobacillus abundance by RNA sequencing
blood vessel density2 yearsThe blood vessel density will be measured by OCT
Vaginal Health Index (VHI)2 yearsVHI to be measured on exam

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026